Gene directed enzyme prodrug therapy for cancer

Advanced Drug Delivery Reviews

Volumn 26, Issue 2-3, 1997, Pages 173-184

  McNeish, I A ^a   Searle, P F ^a   Young, L S ^a   Kerr, D J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cancer gene therapy; Cytosine deaminase; Nitroreductase; Prodrug; Thymidine kinase

Indexed keywords

BLOOD; CELLS; COLIFORM BACTERIA; ENZYMES; GENES; ONCOLOGY; TOXICITY;

GENE THERAPY;

DRUG THERAPY;

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; CYTOSINE DEAMINASE; ENZYME; FLUCYTOSINE; GANCICLOVIR; NITROREDUCTASE; PRODRUG; THYMIDINE KINASE; VIRUS VECTOR;

CANCER; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0031558227     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00033-1     Document Type: Review

References (78)

1. C. Cunningham, M. Dunlop, Genetics of colorectal cancer. Brit. Med. Bull. 50 (1994) 640-655.
2. T. Takahashi, D. Carbone, T. Takahashi, M.M. Nau, T. Hida, I. Linnoila, R. Ueda, J.D. Minna, Wild type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 52 (1992) 2340-2343.
3. Roth, J.A., Nguyen, S., Lawrence, D.D., Kemp, B.L., Carrasco, C.H. et al, (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985-991.
4. W. Schmidt, T. Schweighiffer, E. Herbst, G. Maass, M. Berger, F. Schilder, G. Schaffner, M.L. Birnstiel, Cancer vaccines: the Interleukin-2 dosage effect. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 4711-4714.
5. Dranoff, G., Soiffer, R., Lynch, T., Mihm, M., Jung, K. et al (1997) A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Human Gene Ther. 8, 111-123.
6. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K. et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent specific and long lasting antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
7. M.J. Brunda, L. Luistro, R.R. Warrier, R.B. Wright, B.R. Hubbard, M. Murphy, S.F. Wolf, M.K. Gately, Antitumour and antimetastatic activity of IL-12 against murine tumours. J. Exp. Med. 178 (1993) 1223-1230.
8. + T cells by B7-transfected melanoma cells. Science 259 (1993) 368-370.
9. Clinical protocols (1995) Cancer Gene Ther. 2, 67-74.
10. F.L. Moolten, Tumour chemosensitivity conferred by inserted herpes thymidine kinase genes; paradigm for a prospective cancer control strategy. Cancer Res. 46 (1986) 5276-5281.
11. S.M. Freeman, C.N. Abboud, K.A. Whartenby, C.H. Packman, D.S. Koeplin, F.L. Moolten, G.N. Abraham, The bystander effect: tumour regression when a fraction of the tumour mass is genetically modified. Cancer Res. 53 (1993) 5274-5283.
12. S.H. Chen, H.D. Shine, J.C. Goodman, R.L. Grossman, S.L.C. Woo, Gene therapy for brain tumours: regression of experimental gliomas by adenovirus mediated gene transfer in vivo. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3054-3057.
13. Z. Ram, K.W. Culver, S. Walbridge, R.M. Blaese, E.H. Oldfield, In situ retroviral mediated gene transfer for the treatment of brain tumours in rats. Cancer Res. 53 (1993) 83-88.
14. Y. Samejima, D. Meruelo, Bystander killing induces apoptosis and is inhibited by forskolin. Gene Ther. 2 (1995) 67-74.
15. M. Mesnil, C. Piccoli, G. Tiraby, K. Willecke, H. Yamasaki, Bystander killing of cancer cell by herpes simplex virus thymidine kinase is mediated by connexins. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1831-1835.
16. G.I. Fishman, D.C. Spray, L.A. Leinwand, Molecular characterisation and functional expression of the human gap junction channel. J. Cell Biol. 111 (1990) 589-598.
17. I.M. Pope, S. Gagandeep, S. Christmas, D. Klatzmann, A.R. Kinsella, G.J. Poston, Suicide gene therapy: an immunological component to the bystander effect . Brit. J. Cancer 73. Suppl. 28 (1996) 17.
18. R.G. Vile, J.A. Nelson, S. Castleden, H. Chong, I.R. Hart, Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54 (1994) 6228-6234.
19. C.A. Mullen, M.M. Coale, R. Lowe, R.M. Blaese, Tumours expressing the cytosine deaminase gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumour. Cancer Res. 54 (1994) 1503-1506.
20. R.G. Vile, H. Chong, S. Castleden, N. Hardwick, C. Upton, Generation of Th-1-like immune responses in a non-immunogenic tumour by HSKtk killing. . Brit. J. Cancer 73, Suppl. 26 (1996) 23.
21. S.H. Chen, K. Kosai, B. Xu, K. Pham-Nguyen, C. Contant, M.J. Finegold, S.L.C. Woo, Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained anti-tumour immunity prolongs survival. Cancer Res. 56 (1996) 3758-3762.
22. B.E. Huber, C.A. Richards, E.A. Austin, Virus directed enzyme prodrug therapy. Ann. New York Acad. Sci. 716 (1994) 104-114.
23. E.A. Austin, B.E. Huber, A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43 (1992) 380-387.
24. L. Anderson, M. Kilstrup, J. Neuhard, Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K-12 - involvement of glnG and purR genes in the regulation of codA expression. Arch. Microbiol. 152 (1989) 115-118.
25. C.A. Mullen, M. Kilstrup, R.M. Blaese, Transfer of the bacterial gene for cytosine deaminase to mammalian cell confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 33-37.
26. B.E. Huber, E.A. Austin, S.S. Good, V.C. Knick, S. Tibbels, C.A. Richards, In vivo antitumour activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53 (1993) 4619-4626.
27. B.E. Huber, E.A. Austin, C.A. Richards, S.T. Davis, S.S. Good, Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumour cells transduced with the cytosine deaminase gene: significant antitumour effects when only a small percentage of tumour cells express the cytosine deaminase gene. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8302-8306.
28. L. Kopper, G.G. Steel, The therapeutic response of three human lines maintained in immune suppressed mice. Cancer Res. 35 (1975) 2704-2710.
29. R.J. Knox, F. Friedlos, M. Jarman, J.J. Roberts, A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37 (1988) 4661-4669.
30. N.P. Michael, J.K. Brehm, G.M. Anzelark, N.P. Minton, Physical characterisation of the E. coli B gene encoding nitroreductase and its overexpression in E. coli K12. FEMS Microbiol. Lett. 124 (1994) 195-202.
31. J.A. Bridgewater, C.J. Springer, R.J. Knox, N. Minton, N.P. Michael, M.K.L. Collins, Expression of the bacterial nitroreductase enzyme in mammalian cells renders them sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A (1995) 2362-2370.
32. A.J. Clark, M. Iwobi, W. Cui, M. Crompton, G. Harold, S. Hobbs, T. Kamalati, R. Knox, C. Neil, F. Yull, B. Gusterson, Selective cell ablation in transgenic mice expressing E.coli nitroreductase. Gene Ther. 4 (1997) 101-110.
33. D. Drabek, J. Guy, R. Craig, F. Grosveld, The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 4 (1997) 93-100.
34. D.G. Miller, M.A. Adam, A.D. Miller, Gene transfer by retroviral vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10 (1990) 4239-4244.
35. K.W. Culver, Z. Ram, S. Wallbridge, H. Ishii, E.G. Oldfield, R.M. Blaese, In vivo gene transfer with retroviral vector-producer cells for the treatment of experimental brain tumours. Science 256 (1992) 1550-1552.
36. R.K. Hurford, G. Dranoff, R.C. Mulligan, R.I. Tepper, Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genet. 10 (1995) 85-89.
37. L. Naldini, U. Blömer, P. Gallay, D. Ory, R. Mulligan, F.H. Gage, I. Verma, D. Trono, In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267.
38. N. Kasahara, A.M. Dozy, Y.W. Kan, Tissue specific targeting of retroviral vectors through ligand-receptor interactions. Science 266 (1994) 1373-1376.
39. F.L. Cosset, S.J. Russell, Targeting retrovirus entry. Gene Ther. 3 (1996) 946-956.
40. J.C. Burns, T. Friedmann, W. Driever, M. Burrascano, J.K. Yee, Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titre and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8033-8037.
41. M.K. Parente, J.H. Wolfe, Production of increased titre retrovirus vectors from stable producer cell lines by superinfection and concentration. Gene Ther. 3 (1996) 756-760.
42. O. Danos, R.C. Mulligan, Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6460-6464.
43. Y. Takeuchi, C.D. Porter, K.M. Strachan, A.F. Preece, K. Gustafsson, F.L. Cosset, R.A. Weiss, M.K.L. Collins, Sensitisation of cells and retroviruses to human serum by (α1-3) galactosyl transferase. Nature 379 (1996) 85-89.
44. Y. Takeuchi, F.L. Cosset, P.J. Lachmann, H. Okada, R.A. Weiss, M.K.L. Collins, Type C retrovirus inactivation by human complement is determined by both viral genome and the producer cell. J. Virol. 68 (1994) 8001-8007.
45. F.L. Cosset, Y. Takeuchi, J.C. Battini, R.A. Weiss, M.K.L. Collins, High titre packaging cells producing recombinant retrovirus resistant to human serum. J. Virol. 69 (1995) 7430-7436.
46. Horwitz, M.S. (1990) Adenoviruses. In: B.N. Field, D.M. Knipe et al. (Eds.), Virology, 2nd ed. Raven Press, New York, pp. 1723-1741.
47. A.J. Bett, L. Prevec, F.L. Graham, Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67 (1993) 5911-5921.
48. E.J. Kremer, M. Perricaudet, Adenovirus and adeno-associated virus mediated gene transfer. Brit. Med. Bull. 51 (1995) 31-44.
49. Y. Yang, K.U. Jooss, Q. Su, H.C.J. Ertl, M. Wilson, Immune responses to viral antigens versus transgene products in the elimination of recombinant adenovirus infected hepatocytes in vivo. Gene Ther. 3 (1996) 137-144.
50. J.F. Engelhardt, X.H. Ye, B. Doranz, J.M. Wilson, Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6196-6200.
51. G.P. Gao, Y.P. Yang, J.M. Wilson, Biology of adenovirus vectors with E1 and E4 deletions for liver directed gene therapy. J. Virol. 70 (1996) 8934-8943.
52. R.J. Parks, L. Chen, M. Anton, U. Sankar, M.A. Rudnicki, F.L. Graham, A helper dependent adenovirus vector system - removal of helper virus by CRE-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13565-13570.
53. J.T. Douglas, B.E. Rogers, M.E. Rosenfeld, S.I. Michael, M.Z. Feng, D.T. Curiel, Targeted gene delivery by tropism modified adenoviral vectors. Nature Biotechnol. 14 (1996) 1574-1578.
54. R.D. Sullivan, E. Lewis, M.P. Sykes, A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res. 38 (1959) 3784-3792.
55. P.G. De Takats, D.J. Kerr, C.J. Poole, H.W. Warren, C.S. McArdle, Hepatic artery chemotherapy for metastatic colorectal carcinoma. Brit. J. Cancer 69 (1994) 372-378.
56. Y. Sasaki, I. Shingi, Y. Hesegawa, S. Nakano, O. Ishikawa, H. Ohiyishi, K. Taniguchi, H. Koyama, T. Iwagana, Changes in distribution of hepatic blood flow induced by intra-arterial infusion of Angiotensin II in human hepatic cancer. Cancer 55 (1985) 311-316.
57. S. Bencimol, A. Fuks, S. Jothy, N. Beauchemin, K. Shirota, C. Stanners, Carcinoembryonic antigen, a human tumour marker, functions as an intercellular adhesion molecule. Cell 57 (1989) 327-334.
58. F. MacDonald, R. Bird, H. Stokes, B. Russel, J. Crocker, Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours. J. Clin. Pathol. 41 (1988) 260-264.
59. H. Shrewe, J. Thompson, M. Bona, L. Hefta, A. Maruya, M. Hassauer, J. Shively, S. Von Kleist, W. Zimmermann, Cloning of the complete gene for CEA: Analysis of its promoter indicates a region conveying cell type-specific expression. Mol. Cell. Biol. 10 (1990) 2738-2748.
60. P.A. Hall, C.M. Hughes, S.L. Staddon, The c-erb B2 proto-oncogene in human pancreatic cancer. J. Pathol. 161 (1990) 195-200.
61. D.P. Hollywood, H.C. Hurst, A novel transcription factor, OB2-1, is required for overexpression of the proto-oncongene c-erb B2 in mammary tumour lines. EMBO J. 12 (1993) 2369-2375.
62. R.J. Knox, F. Friedlos, R.F. Sherwood, R.G. Melton, G.M. Anzelark, The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954): II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44 (1988) 2297-2301.
63. C.J. Springer, P. Antonin, K.D. Bagshawe, F. Searle, G.M.F. Bisset, M. Jarman, Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33 (1990) 677-681.
64. V.R. Muzykantov, D.V. Sakhanov, V.V. Sinitsyn, S.P. Domogatsky, N.V. Gonchanov, S.M. Danilov, Specific killing of human endothelial cells by antibody conjugate glucose oxidase. Anal. Chem. 169 (1988) 383-389.
65. U. Kuefner, U. Lohrmann, Y.D. Montejano, K.S. Vitols, F.M. Huennekens, Carboxypeptidase-mediated release of methotrexate from methotrexate-a-peptides. Biochemistry 28 (1989) 2288-2297.
66. E. Haenseler, A. Esswien, K.S. Vitols, Y. Montejano, B.M. Mueller, R.A. Reinsfeld, F.M. Huennekens, Activation of methotrexate-α-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry 31 (1992) 891-897.
67. M.G. Battelli, A. Abbondanza, P.L. Tazzari, A. Dinota, S. Rizza, G. Grassi, M. Gobbi, F. Stirpe, Selective cytotoxicity of an oxygen-radical generating enzyme conjugated to a monoclonal antibody. Clin. Exp. Immunol. 73 (1988) 128-133.
68. Andrianomenjanahary, S., Dong, X., Florent, J.C., Gandel, G., Gesson, J.P, Jecquesy, J.C., Koch, M. et al (1992) Synthesis of novel targeted pro-prodrugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate. Bioorg. Med. Chem. Lett. 2, 1093-1096.
69. Rowlison-Busza, G., Bamias, A., Krausz, T. and Epenetos, A.A. (1991) Cytotoxicity following specific activation of amygdalin. In: A.A. Epenetos (Ed.), Monoclonal Antibodies. Applications in Clinical Oncology. Chapman and Hall, London, pp. 179-184.
70. A. Bukhari, T.A. Connors, A.M. Gilsenan, W.C.J. Ross, M.J. Tisdale, G.P. Warwick, D.E.V. Wilman, Cytotoxic agents designed to be selective for liver cancer. J. Natl. Cancer Inst. 50 (1973) 243-247.
71. H.J. Haisma, E. Boven, M. Van Muijen, R. Devries, H.M. Pinedo, A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Brit. J. Cancer 66 (1992) 474-478.
72. T.A. Shepherd, L.N. Jungheim, D.L. Meyer, J.J. Starling, A novel targeted delivery system utilizing a cephalosporinoncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer. Bioorg. Med. Chem. Lett. 1 (1991) 21-26.
73. P.M. Wallace, P.D. Senter, In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjug. Chem. 2 (1991) 349-352.
74. U. Sahin, F. Hartmann, P.D. Senter, C. Pohl, A. Enigert, V. Diehl, M. Pfreundschuh, Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res. 50 (1990) 6944-6948.
75. G.S. Bignami, P.D. Senter, P.G. Grothaus, K.J. Fisher, T. Humphreys, P.M. Wallace, N-(4′-hydroxyphenylacetyl)-palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res. 52 (1992) 5759-5764.
76. D.E. Kerr, P.D. Senter, W.L. Burnett, D.L. Hirschberg, I. Hellstrom, K.E. Hellstrom, Antibody-penicillin V-amidase conjugates kill antigen-positive tumour cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 31 (1990) 202-206.
77. V.M. Vrudhula, P.D. Senter, K.J. Fischer, P.M. Wallace, Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin G amidase conjugate. J. Med. Chem. 36 (1993) 919-923.
78. L. Chen, D.J. Waxman, Intratumoural activation and enhanced chemotherapeutic effect of ozazo-phospharines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55 (1995) 581-589.